The prospective case series demonstrates the efficacy of the combination in second- and later-line treatment. Targeted therapies directed toward tumor genotype should be considered in addition to standard-of-care regimens. Menstrual blood HPV testing shows 100% match with cervical smears—non-invasive, accurate, and preferred by most women. Tumor mutations were even detected in early-stage disease. The findings reaffirm concurrent chemoradiotherapy as a cornerstone of treatment. The global burden of cervical cancer, as well as cervical cancer mortality, is predicted to increase substantially by 2030. A team of researchers aimed to analyze the genetic expression and prognostic value of selenoprotein gene mutations. Based on these results, a three-diode laser vaginal session enhances and favors the complete closure of VVFs. Deep learning algorithms combined with MRI could have a major impact on diagnosing patients with high-risk disease. A Mendelian randomized analysis was performed to determine the effects of anti-CD20 antibodies on endometrial cancer. This could be a needed breakthrough for those predisposed to breast and ovarian cancer mutations. There is a compelling case for the PK benefit of GLP-1s on certain cancer cell lines. Krystina Dunston spoke about the findings of a study which showed potential in slowing tumor growth in endometrial cancer. Pembrolizumab plus chemoradiotherapy was shown to improve survival in advanced cervical cancer. Dr. Andrew Hertler spoke about the biggest challenges, and most promising treatments associated with endometrial cancer care. A study identified possible prognostic factors and survival patterns based on histology type in endometrial cancer patients. A study analyzed the correlation between cancer-related cognitive impairment and neurotransmission pathways. Dr. Andrew Hertler explains why health disparities exist for Black women with ovarian cancer. Sexual counseling training in gynecological cancers is effective at generating increased awareness among midwifery students. The FDA approved dostarlimab-gxly with carboplatin and paclitaxel for endometrial cancer.